Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.36 |
| ▸ | RAD52 | P43351 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.30 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.30 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 4/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25676841 | 0.88 | HTR2C (0.33) | HTR2C | |
| SCHEMBL18354228 | 0.83 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL18686180 | 0.83 | TSHR (0.36) | HTR2CNPSR1LMNATSHRALDH1A1 | |
| SCHEMBL14702361 | 0.77 | NAAA (0.36) | NAAAEPHX1TSHRALDH1A1CYP3A4 | |
| SCHEMBL22971403 | 0.77 | CYP1A2 (0.41) | LMNAALDH1A1 | |
| SCHEMBL16943384 | 0.77 | NAAA (0.36) | NAAAEPHX1TSHRALDH1A1CYP3A4 | |
| SCHEMBL26298907 | 0.75 | KDM4E (0.38) | LMNATSHR | |
| SCHEMBL10000217 | 0.75 | NAAA (0.33) | NAAAEPHX1TSHRALDH1A1CYP3A4 | |
| SCHEMBL13886401 | 0.74 | DGKA (0.45) | LMNAALDH1A1PRSS1PRSS2PRSS3 | |
| SCHEMBL4460727 | 0.74 | LMNA (0.62) | NAAALMNAALDH1A1PRSS1PRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160303242-A1 | Pharmaceutically Active Agent Complexes, Polymer Complexes, and Compositions and Methods Involving the Same | DURECT CORPORATION (US) | 2016-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160303242-A1 | Pharmaceutically Active Agent Complexes, Polymer Complexes, and Compositions and Methods Involving the Same | PAICS, PARG, PUF60 | HTR2C 3961/4885NAAA 791/4885RAD52 1428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.